Last reviewed 2026-05-23 · How we verify

i-PRF application on palatinal wound healing

Inonu University · Phase 1 active Biologic ✓ Verified May 2026 Quality 0/100

i-PRF application on palatinal wound healing is a Biologic drug developed by Inonu University. It is currently in Phase 1 development.

i-PRF application has been studied in the context of palatinal wound healing as part of a clinical trial comparing its effects to other platelet concentrates. The specific mechanism of i-PRF is unknown, but it has been investigated for its potential to aid in wound healing and reduce inflammation.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	i-PRF application on palatinal wound healing
Sponsor	Inonu University
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effects of Platelet Concentrates on Palatal Wound Healing (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

i-PRF application on palatinal wound healing CI brief — competitive landscape report
i-PRF application on palatinal wound healing updates RSS · CI watch RSS
Inonu University portfolio CI

Frequently asked questions about i-PRF application on palatinal wound healing

What is i-PRF application on palatinal wound healing?

i-PRF application on palatinal wound healing is a Biologic drug developed by Inonu University.

Who makes i-PRF application on palatinal wound healing?

i-PRF application on palatinal wound healing is developed by Inonu University (see full Inonu University pipeline at /company/inonu-university).

What development phase is i-PRF application on palatinal wound healing in?

i-PRF application on palatinal wound healing is in Phase 1.

Manufacturer: Inonu University — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing